Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 7:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–45 of 21 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed Not applicable Interventional Accepts healthy volunteers

The Impact of Lorazepam on Cognition in APOE e4 Carriers

NCT00586430
Conditions
Alzheimer's Disease
Interventions
lorazepam, placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Scottsdale, Arizona
Conditions
Nausea, Vomiting
Interventions
ABH gel, placebo
Drug · Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Richmond, Virginia
Conditions
Pain, Anxiety
Interventions
clonidine, placebo
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
4 Years to 20 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
1
States / cities
Galveston, Texas
Completed Phase 4 Interventional Results available

Oral Sedation During Cervical Dilator Placement

NCT03202550
Conditions
Oral Sedation and Cervical Dilator Pain
Interventions
Oxycodone and Lorazepam (Active Comparator), Placebo Comparator
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Completed Phase 4 Interventional Accepts healthy volunteers

Lorazepam-Induced Toxicity in the Aged

NCT00044642
Conditions
Anxiety Disorders, Generalized Anxiety Disorder
Interventions
Lorazepam
Drug
Lead sponsor
Nathan Kline Institute for Psychiatric Research
Other
Eligibility
60 Years and older
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2007
U.S. locations
2
States / cities
New York, New York • Orangeburg, New York
Active, not recruiting Phase 2 Interventional Results available

Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer

NCT01949662
Conditions
Advanced Cancers
Interventions
Lorazepam, Placebo, Haloperidol decanoate, Questionnaires
Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2028
U.S. locations
1
States / cities
Houston, Texas
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Prescribing Lorazepam for IUD Insertion: Pilot Feasibility Study

NCT06496854
Conditions
Pain, IUD
Interventions
Lorazepam 1 mg, Ibuprofen 800 mg
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Bipolar Disorder, Schizoaffective Disorder, Manic Disorder, Mania, Manic State
Interventions
Pentazocine, Lorazepam
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Belmont, Massachusetts
Conditions
Nausea, Vomiting, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
Decadron®, Benadryl®, Ativan®, ondansetron hydrochloride
Drug
Lead sponsor
University of South Florida
Other
Eligibility
8 Years to 18 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
6
States / cities
Fort Myers, Florida • Orlando, Florida • Tampa, Florida + 3 more
Recruiting Phase 4 Interventional Accepts healthy volunteers

Computational Assessment of GABA Receptor Modulation in PTSD

NCT06852469
Conditions
Stress Disorders, Post-Traumatic
Interventions
Lorazepam 1 mg tablet, Placebo tablet
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
San Diego, California
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

Lorazepam Effects on Neuroimaging Measures

NCT04671836
Conditions
Lorazepam, Neuroimaging
Interventions
Lorazepam 1Mg Tablet, Placebo
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 40 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Glen Oaks, New York
Conditions
Delirium, Respiratory Failure
Interventions
Dexmedetomidine, GABA agonist
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Alcohol Withdrawal, Alcohol Withdrawal Delirium
Interventions
Phenobarbital, Lorazepam
Drug
Lead sponsor
OSF Healthcare System
Other
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Peoria, Illinois
Conditions
Delirium, Locally Advanced Malignant Neoplasm, Metastatic Malignant Neoplasm, Recurrent Malignant Neoplasm
Interventions
Haloperidol, Lorazepam, Placebo, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
2
States / cities
Houston, Texas • Richmond, Virginia
Conditions
Alcohol Withdrawal
Interventions
Lorazepam, Diazepam
Drug
Lead sponsor
Stanford University
Other
Eligibility
19 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
2
States / cities
Palo Alto, California • Stanford, California
Completed Not applicable Interventional Accepts healthy volunteers Results available

Lorazepam, Diphenhydramine Hydrochloride, and Haloperidol Gel in Healthy Volunteers

NCT01204255
Conditions
Healthy
Interventions
lorazepam, diphenhydramine hydrochloride, haloperidol, questionnaire administration, laboratory biomarker analysis
Drug · Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Richmond, Virginia
Conditions
Alcohol Dependence, Anxiety Disorder
Interventions
disulfiram plus lorazepam
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Albuquerque, New Mexico
Conditions
Alcohol Withdrawal Syndrome(AWS)
Interventions
Gabapentin, Lorazepam
Drug
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
21 Years to 70 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2005
U.S. locations
1
States / cities
Charleston, South Carolina
Conditions
Status Epilepticus
Interventions
lorazepam
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
3 Months to 17 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
Alcohol Withdrawal Syndrome
Interventions
Lorazepam (drug), Lorazepam
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
21 Years to 75 Years
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Richmond, Virginia
Conditions
Generalized Anxiety Disorder (GAD)
Interventions
Extended-release lorazepam, Placebo
Drug
Lead sponsor
Edgemont Pharmaceuticals, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
495 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Multiple Locations, California